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Background: The aim of this study was to determine if the treatment with bisphosphonates other anti-resorptive 
and antiangiogenic agents influences the success of regenerative and / or implant treatments. 
Material and Methods: We reviewed the literature from the last 5 years in the PubMed database, using the 
following words: “Sinus Floor Augmentation”[Mesh] OR “Dental Implants”[Mesh]) OR “Guided Tissue 
Regeneration”[Mesh]) AND “Osteonecrosis”[Mesh]. The articles were selected following the inclusion and ex-
clusion criteria and were evaluated using the 22 items of the STROBE declaration. The following PICO clinical 
question was applied: Does the treatment with agents associated with drug osteonecrosis influence the success of 
regenerative and implant treatments? 
Results: The initial search resulted in a total of 27 articles. After eliminating those that did not refer to the topic, 
were duplicated or did not meet the inclusion / exclusion criteria, a full reading of the articles was made evaluat-
ing their methodological quality, obtaining six studies with high methodological quality and two with moderate. 
Conclusions: The literature regarding this topic is scarce, randomized clinical trials would be necessary to es-
tablish protocols relative to implant treatment in patients on antiresorptive treatments. The risk of developing an 
osteonecrosis associated with the regeneration / implant placement in patients with benign bone diseases is scarce, 
but it exists and it should not be underestimated. Especially, in the posterior areas of the jaw, if the duration of 
treatment with BP is greater than 3 years, and if the patient is under therapy with systemic corticosteroids.
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Introduction
The term “Osteonecrosis of the jaws” was introduced 
by Marx in 2003 (1) and later by Ruggiero et al. in 2004 
(2,3). This term refers to bone exposures (in the maxilla 
or mandible) without early healing, associated with the 
use of bisphosphonates (BP). Bagán et al. describes the 
same lesion associated with antiresorptive medication 
in his series of 10 clinical cases, using the term avascu-
lar bone necrosis (4). 
To be considered a Bisphosphonate-related osteonecro-
sis of the jaw it should persist for at least 6-8 weeks in 
the absence of radiation therapy in the affected area; 
and it may – or may not -  be associated with  high mor-
bidity, pain, tooth mobility, halitosis, paresthesia, bone 
sequestration and intraoral or extraoral fistula (5,6). 
Bisphosphonates are frequently used to modulate the 
bone remodeling cycle in benign bone disorders such 
as osteoporosis, osteogenesis imperfecta and Paget’s 
disease. They are also used to prevent and control the 
bone activity of certain malignant neoplasms, such 
as multiple myeloma and bone metastases of prostate 
cancer, breast cancer, among others (7). According to 
their action mechanism, they are divided into two main 
groups: the first generation (non-nitrogen): etidronate, 
clodronate and tiludronate; and those of second and 
third generation (with-nitrogen): alendronate, risedro-
nate, ibandronate, pamidronate and zoledronic acid. 
The route of administration includes the oral and par-
enteral route (7,8). 
The oral BPs have a low absorption rate and have a short 
half-life (between 30 and 120 minutes), with 20 to 80% 
of the substance deposited in the bone (9). However, 
those of intravenous use have a high bioavailability and 
once absorbed in the bone tissue, it can take more than 
10 years to metabolize, and consequently excrete. The 
BP that have a higher binding affinity, in descending or-
der, are: zoledronic acid > alendronate > ibandronate > 
risedronate > etidronate (8,10). According to the Advi-
sory Task Force Group on Bisphosphonate-related Os-
teonecrosis of Jaws until 2007, 190 million treatments 
with bisphosphonates were prescribed worldwide (11). 
These drugs have different common adverse effects: 
esophageal ulcer, atypical fracture of the femur, atrial 
fibrillation and osteonecrosis of the jaw (5,12). Although 
BP are the main pharmacological cause of osteochimio-
necrosis; there are other drugs frequently used, espe-
cially in recent years, in the treatment of osteoporosis 
and bone metastasis; called Anti RANKL monoclonal 
antibodies that can cause the same adverse effect. One of 
these agents is Denosumab (Prolia®, Xgeva®) a highly 
specific human IgG2 monoclonal antibody to the recep-
tor activator of nuclear factor-B ligand (RANKL), in-
hibiting the activity of osteoclasts, reducing resorption 
and increasing bone density. Bevacizumab (Avastin®) 
and Sunitinib (Sutent®), two antiangiogenic drugs, are 
frequently used in oncological patients and can be in-
volved in the pathogenesis of  Medication-related osteo-
necrosis of the jaw (MRONJ) (13-16).
Ruggiero et al. in an update article by the American As-
sociation of Oral and Maxillofacial Surgeons (AAOMS) 
mentions that the incidence of osteonecrosis is higher in 
patients who received high doses of BP during the treat-
ment of neoplastic diseases with metastasis with an in-
cidence of 1 to 10%. This is most likely associated with 
the frequency and dose of the BP prescribed (17-19). On 
the other hand, in the few studies available, it has been 
confirmed that the risk of Osteonecrosis in patients re-
ceiving BP for the treatment of osteoporosis is very low, 
between 1 / 10,000 and 1 / 100,000 patients / treatment 
and year (13,17,20). Patients receiving BP or Deno-
sumab therapy for the treatment of bone metastases and 
multiple myeloma receive monthly doses of intravenous 
(for BP) or subcutaneous (for Denosumab). While pa-
tients with osteoporosis or other bone disease such as 
Paget’s disease (osteitis deformans) require antiresorp-
tive therapy at much lower doses (Denosumab 60mg / 
6months, zoledronic acid 5mg every 1 to 5 years) (21).
Ruggiero & Drew (22) propose a classification that al-
lows the categorization of an Osteonecrosis into dif-
ferent stages according to the severity of its signs and 
symptoms. Subsequently, the AAOMS adapts this clas-
sification including a stage 0 and the patient at risk (3) 
(Table 1). Alternatively, Bagán et al. considered two 
subdivisions within stage II (23). The diagnosis of Os-
teonecrosis is based mainly on the presence of the fol-
lowing characteristics: patient under treatment with BP, 
areas of bone exposed without healing more than 6-8 
weeks and absence of radiotherapy in the craniofacial 
region (19,24). 
Risk factors can be divided into two groups, local fac-
tors, which include surgical treatments (eg, dental ex-
tractions and surgical periodontal procedures) and con-
comitant oral diseases (eg, periodontal diseases, tooth 
decay and abscesses), and systemic factors, such as 
advanced age, tobacco use, corticosteroid therapy, and 
coexisting conditions such as anemia and diabetes (25-
27). According to the AAOMS, the risk of developing 
osteonecrosis in patients who have been exposed to an-
tiresorptive medications for other dentoalveolar opera-
tions, such as dental implant placement and endodontic 
or periodontal procedures is unknown (19). According 
to the literature implant surgery should be avoided in 
patients under intravenous treatment with BP. For pa-
tients undergoing oral BP treatment for less than 3 years 
dental implants can be inserted safely (19). However, 
the patient should always be warned of possible imme-
diate or late risk (19). Most authors agree that the risk 
is closely related to the patient’s condition and the dura-
tion of treatment with antiresorptive agents, but there is 
an increasing number of clinical cases of Osteonecrosis 
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Stage Description
At risk Asymptomatic patient, without apparent necrotic bone, with a history of antiresorptive or antiangiogenic 
treatment.
Stage I Exposed and necrotic bone or fistulas that probes to bone in patients who are asymptomatic and have no evidence 
of infection
Stage II
     
     
Symptomatic patients. Presence of pain and clinical evidence of infection (erythema in the region of the exposed 
bone with or without drainage) in patients with exposed and necrotic bone or a fistula that probes to the bone.
Stage IIa Bone exposure with necrotic bone or a small fistula without bone exposure, but with symptoms: 
Pain and infection of the soft tissues / bone. It is controlled with conservative treatments and does 
not progress
Stage IIb Bone exposure with necrotic bone or a small fistula without bone exposure, but with symptoms: 
Pain and infection of the soft tissues / bone. It is not controlled with conservative treatments and the 
necrosis progresses or the infectious signs derived from it
Stage III
 
Presence of pain and clinical evidence of infection in patients with exposed and necrotic bone or a fistula that 
probes to the bone and one or more of the following:
•  Necrotic bone exposed beyond the region of the alveolar bone resulting in a pathological fracture,
•  Wide osteolysis extending to the lower edge of the lower jaw, or to the floor of the maxillary sinus,
•  Extraoral fistula,
•  Gold-antral or gold-nasal communication
Table 1. Staging of Osteochimionecrosis according to the AAOMS and subdivision proposed by Bagán et al. (23).
after the placement of dental implants (24). Given the 
current controversy on the subject, our main objective is 
to revise the published studies assessing the prognosis 
of rehabilitation treatments with dental implants (with 
or without previous bone regeneration) in patients pre 
or post treatment with antiresorptive agents. The results 
observed were the implant loss, the failure of the regen-
erative treatments and the incidence of Osteonecrosis.
Material and Methods
A bibliographic review was made in the PubMed 
database during the last 5 years using the follow-
ing words: “Sinus Floor Augmentation”[Mesh] 
OR “Dental Implants”[Mesh]) OR “Guided Tissue 
Regeneration”[Mesh]) AND “Osteonecrosis”[Mesh]. 
The articles included were retrospective, prospective ob-
servational studies and series of clinical cases focused on 
the subject, including patients undergoing treatment with 
agents associated with drug osteonecrosis and submitted 
to a bone guided regeneration procedure and / or den-
tal implants, written in English, Spanish or Portuguese, 
evaluated on humans. Experimental laboratory studies; 
animal studies; studies in which the main topic was not 
the relationship between dental implants and / or regen-
eration and systemic therapy with antiresorptive agents 
and duplicate articles, were excluded from the review. 
Two authors (AMG and CPY) independently reviewed 
all articles and extracted data from each study including 
first author, publication year, population sampled, type of 
study, gender, age / average range, risk factors, follow-
up, indication of the use of bisphosphonate, adminis-
tration route, type of bisphosphonate, duration of treat-
ment, incidence of MRONJ, stage of MRONJ, location 
of MRONJ, lost implants, position of the lost implants 
and type of graft. The results obtained by AMG and 
CPY were compared and reviewed by a third researcher 
(MAS). The authors (EJS y JLL) reviewed the final draft 
of the manuscript as a further quality check.
The eight articles reviewed were evaluated using the 22 
items of the STROBE declaration (STrengthening the 
Reporting of OBservational studies in Epidemiology). 
The studies that presented at least 15 of the 22 criteria 
were considered as having a “high methodological qual-
ity “; those who presented 8 to 14 of the criteria were 
considered as having “moderate methodological qual-
ity”; and those studies that presented less than 7 criteria 
were considered  as “low methodological quality” (28). 
This article was written according to the PRISMA state-
ment (Preferred Reporting Items for Systematic Reviews 
and Meta-Analyzes for Protocols) and the following 
PICO clinical question was used: Does the treatment 
with agents associated with drug osteonecrosis influence 
the success of regenerative and implant treatments? (29).
Results
In the initial search we obtained a total of 27 articles 
with which a manual review was made by reading the 
summaries, in order to exclude all those that did not 
refer to the topic, were duplicated or did not meet the 
inclusion / exclusion criteria, from this review we elimi-
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nated 19 articles (Fig. 1). A full reading of the articles 
was made, evaluating their methodological quality, ob-
taining a total of 8 articles, 6 of them with a high meth-
odological quality and 2 with moderate (Table 1). We 
included in this review all articles of high and moder-
ate quality, obtaining 6 observational, descriptive and 
retrospective series of clinical cases; 1 Observational, 
Descriptive and prospective case series and 1 Cohort 
Prospective Analytical Study. 22 articles were included 
due to their relevance and interest for the subject, 11 
are reviews of the literature, 5 are systematic reviews, 
2 retrospective cohort studies, 2 meta-analyzes, a series 
of clinical cases and a letter to the editor.
In Table 2 we present a summary of the data that we 
consider most relevant in the studies reviewed.
Fig. 1. Diagram of the search process and results.
From the collected data we obtained a sample of 135 
patients, the great majority being women (n = 81) in 
which the age varies between 42 and 79 years. The main 
indication and method of administration for the use of 
bisphosphonates was osteoporosis and the oral route, 
except in the study by Matsuo et al. that used a sample 
of oncological patients in treatment with intravenous 
bisphosphonates. Eighty-two patients developed osteo-
necrosis associated to implants, with a higher preva-
lence in the posterior sectors of the maxilla (n = 22) and 
mandible (n = 33). Forty patients were under treatment 
with IV BP (Average of Duration of BP treatment: 44 
months) and 42 where under oral BP (Average of Dura-
tion of BP treatment: 56 months). Only one of the re-
viewed articles focuses on regenerative procedures. 
Discussion
In the studies included most patients under treatment 
with intravenous bisphosphonates were receiving zole-
dronic acid and the majority of patients under treatment 
for osteoporosis with oral bisphosphonates were taking 
alendronic acid (9,24-27,30). Kwon et al. and López-
Cedrún et al. show that the majority of patients who 
developed Osteonecrosis associated with the placement 
of dental implants received alendronate orally (24,27). 
Holzinger et al. studied the temporal relationship be-
tween the occurrence of Osteonecrosis and the moment 
of implant placement, concluding that the risk of develop-
ing Osteonecrosis is greater and more accelerated when 
the implantation has been performed after the start or 
during the therapy with bisphosphonates (9). Within the 
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Table 2. Evaluation following the criteria of the STROBE Declaration (x - Meets the criteria; 0 - Does not meet the criteria).
same subject, Giovannacci et al. reported that the aver-
age duration of treatment with bisphosphonates before 
the onset of osteonecrosis was longer for patients under-
going oral bisphosphonates than patients undergoing in-
travenous therapy (26). Jacobsen et al. also reported in 
their study that the average duration of treatment with 
bisphosphonates was 38 months in patients who received 
intravenous BP and approximately 50 months in patients 
who received oral BP treatment for osteoporosis (30). On 
the other hand, López-Cedrún et al. and Giovannacci et 
al. present a longer average interval of approximately 5 
and 6 years respectively (24,26). 
The study by Matsuo et al. is particularly interesting, 
being the only study that focuses exclusively on cancer 
patients and treatment with intravenous bisphosphonates. 
In addition, it only assesses patients who started bisphos-
phonate therapy after implant treatment. In their conclu-
sions, the risk for osteonecrosis induced by intravenous 
therapy with bisphosphonates should be evaluated sepa-
rately in patients receiving monthly doses and those who 
receive an injection every 6 months, since both the pri-
mary disease and the cumulative dose are completely dif-
ferent between the two uses (16). 
Some authors affirm that not only implant surgery, but 
also the existence of the implant itself, seems to be as-
sociated with Osteonecrosis (9,16,24-27). Most articles 
classify Osteonecrosis as “Implant surgery triggered” 
when Osteonecrosis occurs immediately after implant 
placement (2 to 10 months) and “implant presence trig-
gered” in which Osteonecrosis developed after one year 
of implant placement (26). Giovannacci et al. in its retro-
spective study with 15 patients with osteonecrosis around 
dental implants, relates 9 of the cases to the presence of 
the implant itself, considering that the osteonecrosis 
occurred after a time interval of 1 to 15 years after the 
surgical procedure and subsequent successful osseointe-
gration (26). Know et al. analyzed a series of 19 Osteone-
crosis associated with implants in patients under therapy 
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with BP. Of these 19, 3 patients (15.8%) developed Os-
teonecrosis within 6 months after implant surgery. In 5 
patients (26.3%) Osteonecrosis was related to the surgical 
trauma of implant explantation and debridement of the 
bone. However, in the majority of patients (n = 11, 58%) 
Osteonecrosis appeared without any relation to the sur-
gical trauma of the insertion or extraction of the dental 
implant (27). López-Cedrùn et al. in their study present a 
series of 9 patients medicated with oral bisphosphonates 
and with Osteonecrosis around the implants in which 
Osteonecrosis was an early complication (from 1 to 12 
months) in 4 patients (44.4%) and a late complication 
(from 18 to 96 months) in the remaining 5 (55.6%) (24). In 
4 of the 27 patients assessed by Jacobsen et al. implant in-
sertion was performed several months before the start of 
BP therapy; concluding, therefore, that, in these patients, 
the implant itself, and not the surgical insertion, was the 
local factor for the development of Osteonecrosis (30). 
Osteonecrosis associated with dental implants seems to 
preferentially affect the posterior sectors of the mandible 
and the maxilla and, in general, it is a late complication 
unrelated to the operation (24,26,30). In the study by Ja-
cobsen et al. 9 of the 12 patients showed implant failure 
in the mandible or the posterior maxilla (30). The etio-
pathological process of Osteonecrosis remains unclear. 
However, Jacobsen et al. analyzed the necrotic bone of 12 
patients, obtaining as an Histological result Actinomyces 
plates in 7 of the samples, allowing to correlate the pro-
cess of Osteonecrosis with infection, also after starting 
the systemic antibiotic treatment, discomfort and other 
symptoms such as hypoesthesia resolved in all patients 
(30). 
Kwon et al. defend in their article the theory that the in-
creased risk of developing Osteonecrosis in implants al-
ready integrated in patients taking BP could be explained 
by the reduced response to bone remodeling consider-
ing that the bone tissue around a loaded osseointegrat-
ed dental implants is subject to continuous remodeling 
(27). Tam et al. present two cases of osteonecrosis as-
sociated with implants in patients under treatment with 
oral bisphosphonates and propose another justification in 
which the surgical trauma during implant surgery could 
stimulate the postoperative accumulation of the drug at 
implant sites in the patients who maintain bisphospho-
nate therapy after the surgery (25). 
Diseases such as diabetes, corticosteroid treatment and 
smoking habit are identified as predisposing conditions 
for the development of osteonecrosis. However, there 
is no homogeneity of data in the literature. In a study 
by Giovannacci et al. the number of patients receiving 
corticosteroids was higher, especially among oncologi-
cal patients (26). Matsuo et al. in a previous study using 
the same cohort sample of the reviewed article showed 
that the correlations between osteonecrosis and systemic 
factors were significantly low. However, certain local 
factors, particularly oral hygiene and oral infectious dis-
eases (e.j. periimplatitis), showed significantly high cor-
relations (16). 
One of the groups that studied this issue, Kwon et al. 
(2013), identify three characteristic patterns of bone 
destruction of the Osteonecrosis lesion around the im-
plant: i) “frozen type” - abundant bone necrosis around 
the implant and adjacent alveolar bone (areas of necrosis 
are more evident than inflammatory components of soft 
tissue). ii) “osteolytic” - extensive osteolysis around an 
implant with / without sequestration formation (increase 
in soft inflammatory tissue and residual necrotic or vi-
able bone particles similar to conventional osteomyeli-
tis). iii) “en block type” - block sequestration with the 
implant (a considerable amount of implant-bone contact 
is maintained). Six of the assessed patients presented 
“en block type” sequestration, in which maintenance of 
the osseointegration of the implant surface to the sur-
rounding necrotic bone was observed. These findings are 
different from the typical bone destruction induced by 
peri-implant disease. “En bloc type” sequestration seems 
to be one of the characteristics of implant-related Osteo-
necrosis (27). Within the same line of investigation Tam 
et al. report in their study that most of the implants lost 
due to thermal damage and bacterial infection present a 
marginal bone loss or around the dental implant and that, 
in their series of cases, five patients showed bone destruc-
tion around the dental implant resembling an osteomyeli-
tis bone sequestration (25). It is noteworthy that studies 
such as that of Jacobsen et al., identified bacteria, espe-
cially Actinomyces, in biopsy samples of necrotic bone 
from patients with Osteonecrosis, this associated with 
the late failure of the implants leads to certain authors, 
including Holzinger et al., to consider periimplantitis as 
a possible risk factor for Osteonecrosis. However, they 
concluded that randomized and prospective clinical trials 
are necessary to establish this relationship (9,16,30,31). 
All the suggested theories regarding MRONJ, proposed 
by the different authors, are summarized in table 3.
On the same subject Matsuo et al. with a sample of on-
cological patients, in treatment with intravenous bisphos-
phonates, identifies the decrease in activities of daily 
living (ADL) - associated with chemotherapy (the stan-
dard therapy for these patients) - and consequently poor 
maintenance of oral hygiene as one of the main causes for 
the development of osteonecrosis associated with dental 
implants (16). 
The majority of osteonecrosis present in the studies re-
viewed are stage II or III, in which pain was the main 
presenting symptom, sometimes associated with signs 
of infection, such as swelling and purulent discharge 
(16,24,26). It is worthy of mention that not all studies 
classify Osteonecrosis in the stages proposed by the 
AAOMS, considering that stage I is usually asymptom-
atic it is possible to presume that some Osteonecrosis are 
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underdiagnosed (16). Khoury et al. present very favor-
able results in their series of cases in which 15 patients 
in treatment with bisphosphonates and with severe bone 
atrophy were treated with bone grafts using mandibular 
bone blocks. The general results were similar to those of 
patients without bisphosphonate treatment. However, it 
should be mentioned that the authors selected the patients 
to be treated, assessing the risks of each patient, reject-
ing the regenerative treatment in high-risk patients. Ac-
cording to the authors, part of the success of their results 
is due to a correct anamnesis to evaluate the individual 
risk, a good surgical protocol, with primary closure of 
the wounds and with prophylactic and postoperative an-
tibiotic treatment (32). None of the articles refers to the 
quality of prosthetic rehabilitation, except Holzinger et 
al. that cites this factor as one of the limitations of the 
study design (9). Only one article by Tam et al. mentions 
the professional’s experience as a possible risk factor for 
the development of Osteonecrosis associated with place-
ment and implants (25). All the articles reviewed focus 
on the treatment with bisphosphonates, there being no 
studies at the time of writing this article that meet the 
inclusion / exclusion criteria on the role of other agents 
(anti RANKL, angiogenesis inhibitors)  in osteonecrosis 
associated with implants / regenerations.
There is a consensus in the literature on the contraindi-
cation of implant placement in cancer patients treated 
with intravenous antiresorptive medication and a general 
favorable opinion about the treatment with dental im-
plants in osteoporotic patients submitted to oral bisphos-
phonates, provided that an individual risk assessment is 
performed prior to surgery. The individual risk depends 
on the primary disease and its treatment, antiresorptive 
medication (substance, duration of application, and fre-
quency of application), concomitant therapy and other 
risk diseases in implantology (diabetes etc). Other risk 
factors (not associated with antiresorptive medication) 
include smoking, advanced age, chronic physical inac-
tivity, obesity, female patients and poor oral hygiene. It 
is essential to explain the potential risk of Osteonecro-
Authors Suggested Theories
Kwon et al. (2013) MRONJ in implants already integrated  Reduced bone remodeling around a loaded 
osseointegrated dental implants.
Tam et al. (2014) MRONJ in patients under oral BP  The trauma during implant surgery stimulates the 
postoperative accumulation of the drug at implant sites in patients who maintain bisphosphonate 
therapy after the surgery.
Jacobsen et al. (2013, 
Holzinger et al. (2014)
Biopsy samples of necrotic bone from patients with MRONJ  Infection by Actinomyces – 
Periimplantitis.
Matsuo et al. (2016) Sample of oncological patients with MRONJ  Decrease in activities of daily living (ADL) - 
associated with chemotherapy - and consequently poor maintenance of oral hygiene.
Table 3. Suggested theories regarding implant placement, osteomodulating agents and MRONJ.
sis not only in patients under treatment with bisphos-
phonates who will undergo implant surgery but also in 
patients who already have osseointegrated implants and 
who must initiate antiresorptive therapy, due to the risk 
of developing a late “implant triggered” osteonecrosis.
In conclusion: i) The literature concerning this topic is 
scarce and consists mainly of clinical cases, series of cas-
es and some retrospective studies. Randomized clinical 
trials are necessary to establish protocols for these pa-
tients. ii) The risk of developing an Osteonecrosis associ-
ated with regeneration and / or implant placement in pa-
tients with benign bone diseases is low, but it exists and 
should not be underestimated. Especially, and according 
to some authors, in the posterior areas of the jaw, if the 
duration of treatment with BP is greater than 3 years, and 
if the patient is under therapy with systemic corticoste-
roids.  iii) An implant failure due to periimplantitis or 
osteonecrosis can present relatively similar clinical mani-
festations; however, the “en bloc sequestration” seems to 
be a pathognomonic feature of the MRONJ, thus allowing 
to correctly diagnose the cause of the failure. iv) A strict 
surgical protocol with primary closure of the wound, 
without tension, seems to reduce the risk of osteochimio-
necrosis and it is essential that patients attend periodic 
check-ups after medical-surgical treatment. v) There is 
not, at least until the writing of this article, literature that 
meets the inclusion criteria on patients under treatment 
with anti RANKL monoclonal agents and antiangiogenic 
drugs, so the recommendations are, for now, to proceed 
with these patients the same way as in patients with 
bisphosphonates, especially when considering that many 
of these patients, mainly the ones under Denosumab, 
were previously treated with bisphosphonates to control 
benign bone pathology.  vi) The prescribing specialist 
must be aware of the risk and refer the patient to a dentist 
for evaluation before starting treatment, thus allowing 
the opportunity to offer the best rehabilitation treatment 
according to the patient osteomodulating therapy, and in 
case the patient already has osseointegrated implants, to 
warn and explain the risk of MROJ, (Table 4).
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Gender 6W / 5W, 4M (#) 15W ND 13W 6 W 17W, 2M 8W, 1M 11W, 3M 
Age / average 
range (years) 
65.2 / 63.43 (#) 55 - 72 56.5 / 57 
(*) 
51.9 - 79.1 71,83 42-85 66 ND 
Number of cases / 
controls 
15 (6 / 9) (#) 15 6 / 38 (*) 13 6 19 9 14 
Risk factor's Tob, 
Cort, 
SC (An, Diab) 
ND Hygiene Tob, 











ND > 36 24 ND 26 24 3 – 36 ND 
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83.7 / 27.8 (#) 3 - 120 27 -  
19.9 













IV: 2 (#) 
ND ND ND ND ND I – 1 










ND ND M: 1 
M: 12 
PM: 2 





PM - 1 
Pm - 7 




Implants in BP 
users / controls 
34 71 19 (**) 47 19 ND 57 23 
Lost implants ND 1(***) 1 30 12 23 12 23 
Position of the 
lost implants 
















Grafts ND 34: Lg 
13: Vg 
ND ND ND ND ND ND 
Table 4. Summary of studies included in the review. 
OD&RS-SCC: Observational, Descriptive and Retrospective Study of a Series of Clinical Cases;  OD&PS-SCC: Observational, Descriptive and 
Prospective Study of Series of Clinical Cases; PA-CS: Prospective Analytical Cohort Study; W: Women, M: Men; ND: Data not available; Tob: 
Tobacco; Cor: Corticotherapy; An: Anemia;: Diab: Diabetes; SC: Systemic Conditions; Hyp: Hypertension; HL: Hodgkin Lymphoma; G-6-PD-
d: G-6-PD deficiency; Chem: Chemotherapy; Coex cond: Coexisting conditions; Ost: Osteoporosis; Bc: Breast cancer; Kc: Kidney cancer ; Bc: 
Breast cancer;  Ost: Osteoporosis; Mm: Multiple myeloma; Lc: Lung cancer, Lc; HL: Histiocytosis Langerhans; Pr: Polymyalgia rheumatic; Pc: 
Cancer prostate; Intr: Intravenous; Ia: Ibandronic acid; Aa: Alendronic acid; Zc: Zoledronic acid; Iban: Ibandronate; Ris: risedronate; Alen: 
alendronate; Ris: Risedronate; Pam: Pamidronate; Clo: Clodronate: Lg: Lateral graft; Vg: Vertical graft; M: maxilar; m: mandibule; PM: Poste-
rior maxilla; AM: Anterior maxilla; Pm: Posterior mandible; Am: Anterior mandible; (#) G1 (implant surgery triggered) / G2 (Implant presence 
triggered); (*) Patients taking BP and with implants / Patients taking BP without implants;  (**) Total number of implants in the 6 patients who 
developed Osteonecrosis associated or not to the implants; (***) Implant with immediate loading (removed after 5 months of loading due to 
movement).
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